IL17A and COVID-19: Recent reviews showed evidence that increased Th17 cell activation and IL-17 signaling were found in the plasma and lung of COVID-19 patients and were also linked to critical illness in COVID-19, which may lead to an increased likelihood of lung injury and respiratory failure [19, 20].